NEW YORK (GenomeWeb News) – LED Medical Diagnostics this week announced an agreement to form a collaboration to develop and commercialize a progression-risk assessment test for oral cancer.

The agreement is with BC Cancer Agency to form a relationship with Genome British Columbia. The test, LED said, is based on loss of heterozygosity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.